UY39756A - Compuestos para la degradación dirigida de la tirosina cinasa de bruton - Google Patents

Compuestos para la degradación dirigida de la tirosina cinasa de bruton

Info

Publication number
UY39756A
UY39756A UY0001039756A UY39756A UY39756A UY 39756 A UY39756 A UY 39756A UY 0001039756 A UY0001039756 A UY 0001039756A UY 39756 A UY39756 A UY 39756A UY 39756 A UY39756 A UY 39756A
Authority
UY
Uruguay
Prior art keywords
btk
compounds
dsm
formula
linker
Prior art date
Application number
UY0001039756A
Other languages
English (en)
Inventor
T Hopkins Brian
Isaac Marx
Marta Nevalainen
M Guckian Kevin
Don Anderson Corey
Eric Stefan
Young Ahn Jae
Welzel O’SHEA Morgan
L Yap Jeremy
Xinpeng Cheng
Original Assignee
Biogen Ma Inc
C4 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, C4 Therapeutics Inc filed Critical Biogen Ma Inc
Publication of UY39756A publication Critical patent/UY39756A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

<p>Esta descripción se refiere a compuestos de Fórmula (A) o una sal farmacéuticamente aceptable de los mismos, capaces de activar la ubiquitinación selectiva de las proteínas Btk a través de las vías de ubiquitina-proteasoma (UPP) y provocar la degradación de las proteínas, Btk BTK—L—DSM (A) donde DSM es un resto de señalización de degradación que se enlaza covalentemente al enlazador L, L es un enlazador que enlaza covalentemente BTK a DSM, y BTK es un resto de unión a Btk representado por la fórmula (I) o la fórmula (II) que está enlazado covalentemente al enlazador L:</p>
UY0001039756A 2021-05-05 2022-05-05 Compuestos para la degradación dirigida de la tirosina cinasa de bruton UY39756A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163184439P 2021-05-05 2021-05-05

Publications (1)

Publication Number Publication Date
UY39756A true UY39756A (es) 2022-11-30

Family

ID=82115630

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039756A UY39756A (es) 2021-05-05 2022-05-05 Compuestos para la degradación dirigida de la tirosina cinasa de bruton

Country Status (12)

Country Link
EP (1) EP4333899A1 (es)
KR (1) KR20240017814A (es)
CN (1) CN117580592A (es)
AR (1) AR125768A1 (es)
AU (1) AU2022268977A1 (es)
BR (1) BR112023023065A2 (es)
CA (1) CA3217417A1 (es)
CO (1) CO2023016743A2 (es)
IL (1) IL308219A (es)
TW (1) TW202309039A (es)
UY (1) UY39756A (es)
WO (1) WO2022235945A1 (es)

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
KR20210132233A (ko) 2014-04-14 2021-11-03 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
BR112017019751A2 (pt) 2015-03-18 2018-05-29 Arvinas Inc composto bifuncional, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou um distúrbio, e para degradar uma proteína alvo em uma célula
WO2016197032A1 (en) 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2988430A1 (en) 2015-07-10 2017-01-19 Arvinas, Inc. Mdm2-based modulators of proteolysis and associated methods of use
WO2017011590A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
RU2743432C2 (ru) 2016-04-06 2021-02-18 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
AU2017250076B2 (en) 2016-04-12 2021-07-22 The Regents Of The University Of Michigan Bet protein degraders
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
KR102173463B1 (ko) 2016-10-11 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
KR20190082989A (ko) 2016-12-01 2019-07-10 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
MX2019007649A (es) 2016-12-23 2019-09-10 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
AU2017382406A1 (en) 2016-12-23 2019-04-18 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
UY37559A (es) * 2017-01-06 2018-05-31 Pharmacyclics Llc Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
AU2018215212B2 (en) 2017-01-31 2022-06-02 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20180353501A1 (en) 2017-06-09 2018-12-13 Arvinas, Inc. Modulators of proteolysis and associated methods of use
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
EP3658548A1 (en) 2017-07-28 2020-06-03 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019186358A1 (en) * 2018-03-26 2019-10-03 Novartis Ag 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
EP3774804A1 (en) * 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
AU2019249849C1 (en) 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
JP2021521192A (ja) 2018-04-13 2021-08-26 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンドおよび同リガンドを含む二機能性化合物
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
EP3935050A4 (en) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT
CA3130469A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
US20230025892A1 (en) * 2019-10-30 2023-01-26 Biogen Ma Inc. Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
EP4051679A1 (en) * 2019-10-30 2022-09-07 Biogen MA Inc. Condensed pyridazine or pyrimidine as btk inhibitors
CA3162364A1 (en) 2019-12-20 2021-06-24 Gesine Kerstin Veits Protein tyrosine phosphatase degraders and methods of use thereof
EP4146655A1 (en) * 2020-04-30 2023-03-15 BeiGene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use

Also Published As

Publication number Publication date
CN117580592A (zh) 2024-02-20
WO2022235945A1 (en) 2022-11-10
AU2022268977A1 (en) 2023-11-30
CO2023016743A2 (es) 2023-12-29
BR112023023065A2 (pt) 2024-01-30
CA3217417A1 (en) 2022-11-10
TW202309039A (zh) 2023-03-01
AR125768A1 (es) 2023-08-09
KR20240017814A (ko) 2024-02-08
IL308219A (en) 2024-01-01
EP4333899A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
PA8799101A1 (es) Compuestos tienopirimidina y pirazolopirimidina y su uso como inhibidores de quinasa mtor y quinasa p13
PA8591701A1 (es) Derivados de pirrolopirimidina
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
BRPI0515628A (pt) composto de 2-morfolina-4-pirimidona
UY27169A1 (es) Derivados del ácido isoftálico como inhibidores de metalproteinasas de la matriz
BR0312729A (pt) Novos derivados de indol-3-enxofre
ECSP067044A (es) Compuestos para el tratamiento de trastornos inflamatorios
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
AR066972A1 (es) Derivados azapeptidicos
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
UY27658A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinación para el tratamiento de enfermedades
CY1118583T1 (el) Σταθερες δοσολογικες μορφες ανθελονοσιακων σπιρο και δισπιρο 1,2,4-τριοξολανιων
CO2021014210A2 (es) Compuestos de pirrol
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
DOP2001000268A (es) Derivados puente de piperazina
UY39756A (es) Compuestos para la degradación dirigida de la tirosina cinasa de bruton
ES2190471T3 (es) Procedimiento para producir derivados de guanidina, intermedios de dichos compuestos y su produccion.
BRPI0408689A (pt) derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
UY27034A1 (es) Derivados de pirimidina
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana